牽手一年零七個月后，安泰保險和同行哈門那公司在本周二放棄了它們價值350億美元的合并計劃。

兩家保險商的合并在2016年的總統選舉中受到指責。今年1月底，它們表示聯邦法官和司法部站在了一起，不讓它們合二為一。因此，安泰和哈門那同意叫停此事。按哈門那的流通在外股份計算，這項合并的價值為340億美元。

預計安泰將向哈門那支付10億美元稅前“分手費”，這還不包括給律師和投行的服務費。

這次代價高昂的分手事件出現后，我們對去年未能成功的大規模合并案例進行了整理。

我們還按估算成本給這些案例排了序，這些數字由市場研究機構Dealogic提供，依據是相關公司的全面攤薄股份和債務。

6. KLA-Tencor和泛林集團：115億美元

兩家公司均來自半導體行業，2015年10月商定合并事宜。大約一年后，它們放棄了此項方案，原因是司法部以反壟斷為由予以反對。司法部認為，這兩家公司的合并將危及生產計算機芯片制造設備的對手企業。

5. 安邦保險和喜達屋：155億美元

最初，中國的安邦保險和萬豪國際在追求喜達屋的過程中勢均力敵，但安邦在去年3月中旬把喜達屋爭取到了自己這邊。16天后，安邦保險突然收回了收購要約，說原因是“考慮到市場情況”。喜達屋和萬豪國際最終敲定了價值136億美元的合并方案。

4. 安泰保險和哈門那公司：350億美元

去年10月安泰在提交給美國證監會的文件中稱：“我們打算全力維護對哈門那的收購?！钡A盛頓聯邦法官表示此項合并有悖于反壟斷規定后，安泰就不再堅持此事。

3. 哈里伯頓和貝克休斯：387億美元

兩大石油公司2014年11月決定合并。但出于對壟斷的擔心，司法部在2016年4月請求法院叫停此事，而歐盟監管部門預計也會表示反對。最終，哈里伯頓同意支付35億美元的分手費。

2. Energy Transfer Equity和Williams：550億美元

達科他州輸油管道項目Dakota Access Pipeline承建商Energy Transfer Partners旗下的Energy Transfer Equity（ETE）去年6月份決定收回對輸油管道運營商Williams的報價。ETE做出此項決定的原因是其法律顧問無法將此舉納入免稅合并范疇，但ETE并未因此遭受損失。

1. 輝瑞和艾爾健：1600億美元

輝瑞本打算把艾爾建的愛爾蘭總部（愛爾蘭稅率較低）定為自己的新總部。但奧巴馬政府對公司稅收倒置的情況不是很滿意。因此，美國財政部和國稅局去年4月份頒布規定，極大地壓縮了將總部遷至海外給企業帶來的益處，從而終結了此項合并計劃。輝瑞支付的分手費不多，只有1.50億美元。（財富中文網）

譯者：Charlie

After courting for a year and seven months, insurance companies Aetna and Humana axed their $35 billion merger plan Tuesday.

The two insurers, whose deal came under fire during the 2016 presidential elections, said that late in January, a federal judge had sided with the Department of Justice, blocking the proposed hookup. As a result Aetna and Humana agreed to call it quits on the deal, which would be valued at $34 billion based on Humana's shares outstanding only.

Aetna is expected to pay Humana $1 billion pretax as a result of the breakup—not including the fees expected to go to lawyers and bankers for their services.

In honor of that costly divorce, here's a list of companies in the last year that were prepared to form a massive partnership, only to break up.

The deals are ordered by their estimated cost, as calculated by Dealogic on the basis of their fully diluted shares and including debt.

6. KLA-Tencor and Lam Research: $11.5 billion

The two companies, both in the semiconductor industry, agreed to merge in October 2015. Roughly a year later, they called it quits when the Department of Justice opposed the deal on antitrust concerns. According to the DOJ, a combo would harm rival companies that build machines that put together computer chips.

5. Anbang Insurance and Starwood: $15.5 billion

At first, Chinese company Anbang was a mean opponent for Starwood's other suitor, Marriott International and even won over Starwood by mid-March of last year. Sixteen days later, Anbang abruptly rescinded its offer, citing "market considerations." Starwood and Marriott eventually agreed to merge in a $13.6 billion deal.

4. Aetna and Humana: $35 billion

"We plan to vigorously defend the Humana Acquisition," Aetna wrote in an October filing with the Securities and Exchange Commission. That defense ended when a federal judge in Washington, D.C. said the merger does violate antitrust rules.

3. Halliburton and Baker Hughes: $38.7 billion

The two oil giants decided to join forces in November 2014. But then the DOJ sued to block the merger on antitrust concerns in April 2016, while European Union regulators were expected to raise objections as well. Halliburton agreed to pay a $3.5 billion breakup fee as a result.

2. Energy Transfer Equity and Williams: $55 billion

Energy Transfer Equity, an affiliate of Dakota Access Pipeline-builder Energy Transfer Partners, decided to walk away from its offer for Williams in June. The decision was made after ETE's legal advisors couldn't declare the deal tax-free. ETE wasn't penalized for the breakup.

1. Pfizer and Allergan: $160 billion

Pfizer was ready to name Allergan's headquarters in Ireland (where taxes are lower) as its new home base. But the Obama administration wasn't too pleased with corporate inversions, so in April, the Treasury Department and the Internal Revenue Service unveiled regulations severely limiting the benefits of companies moving their headquarters abroad. That was the death knell for the merger. Pfizer paid a relatively tame $150 million for the breakup.